Cited by 5,198PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Open access

Bryant, Helen E., Schultz, Niklas, Thomas, Huw D., Parker, Kayan M., Flower, Dan, Lopez, Elena, Kyle, Suzanne, Meuth, Mark, Curtin, Nicola J., Helleday, Thomas·2005·Nature

DOI 10.1038/nature03443

Open this paper in CoChat — free account

Abstract

Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours. Here, we show that PARP inhibitors trigger gamma-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.

Integrity signals

Registry

Crossref · 10.1038/nature03443

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M. P., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,058
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
El‐Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 689
Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse
Murcia, J. M., Ricoul, M., Tartier, L., Niedergang, C., Huber, A., Dantzer, F., Schreiber, V., Amé, J., Dierich, A., LeMeur, M., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 629
Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks
Lindahl, T. L., Satoh, M. S., Poirier, G. G., & Klungland, A. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89089-1 · Cited by 611
PARP is important for genomic stability but dispensable in apoptosisPreprint
Wang, Z., Stingl, L., Morrison, C. G., Jantsch, M. F., Łoś, M., Schulze‐Osthoff, K., & Wagner, E. F. (1997) · Genes & Development · doi:10.1101/gad.11.18.2347 · Cited by 557

Show all 26 references

Sorted by citations

Items 501–600 of 1,021

Targeting the DNA Damage Response in Cancer
Ljungman, M. E. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 164
Therapeutic Targeting of the DNA Mismatch Repair Pathway
Martin, S. A., Lord, C. J., & Ashworth, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0821 · Cited by 164
Targeting the DNA repair defect of BRCA tumours
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.006 · Cited by 164
PARP Inhibitor Treatment in Ovarian and Breast Cancer
Weil, M. K., & Chen, A. P. (2011) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2010.12.002 · Cited by 163
Aberrations of the MRE11–RAD50–NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer‐predisposing gene
Bártková, J., Tommiska, J., Oplustilova, L., Aaltonen, K., Tamminen, A., Heikkinen, T., Mistrík, M., Aittomäki, K., BLOMQVIST, C. P., Heikkilä, P., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.09.007 · Cited by 164
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Drew, Y., Ledermann, J. A., Hall, G. D., Rea, D. W., Glasspool, R. M., Highley, M., Jayson, G. C., Sludden, J., Murray, J., Jamieson, D., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.41 · Cited by 163
Self-citation
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
Hanna, C. R., Kurian, K. M., Williams, K., Watts, C., Jackson, A., Carruthers, R., Strathdee, K. E., Cruickshank, G. S., Dunn, L., Erridge, S., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa104 · Cited by 163
A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
Shu, Y., He, X., Liu, Y., Wu, P., & Zhang, Q. (2022) · Clinical Epidemiology · doi:10.2147/clep.s365513 · Cited by 163
Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization
Jönsson, G. B., Naylor, T. L., Vallon‐Christersson, J., Staaf, J., Huang, J., Ward, M. R., Greshock, J. D., Luts, L., Olsson, H. L., Rahman, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0570 · Cited by 163
Repair of Oxidative DNA Damage and Cancer: Recent Progress in DNA Base Excision Repair
Scott, T. L., Rangaswamy, S., Wicker, C. A., & Izumi, T. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5529 · Cited by 162
Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
Gossage, L., & Madhusudan, S. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.001 · Cited by 162
Drugging the Cancers Addicted to DNA Repair
Nickoloff, J. A., Jones, D. V., Lee, S., Williamson, E. A., & Hromas, R. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx059 · Cited by 163
PARP-3 Is a Mono-ADP-ribosylase That Activates PARP-1 in the Absence of DNA
Loseva, O., Jemth, A., Bryant, H. E., Schuler, H., Lehtiö, L., Karlberg, T., & Helleday, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.077834 · Cited by 161
Self-citation
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Stordal, B., Timms, K. M., Farrelly, A. M., Gallagher, D., Busschots, S., Renaud, M., Thery, J., Williams, D., Potter, J., Tran, T., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2012.12.007 · Cited by 161
Targeted Therapy for Breast Cancer Prevention
den Hollander, P., Savage, M. I., & Brown, P. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00250 · Cited by 161
Epithelial ovarian cancer: An overview
Desai, A. (2014) · World Journal of Translational Medicine · doi:10.5528/wjtm.v3.i1.1 · Cited by 161
TRIP13 regulates DNA repair pathway choice through REV7 conformational change
Clairmont, C. S., Sarangi, P., Ponnienselvan, K., Galli, L. D., Csete, I., Moreau, L. A., Adelmant, G., Chowdhury, D., Marto, J. A., & D’Andrea, A. D. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0442-y · Cited by 161
BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality
Murai, J., & Pommier, Y. G. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0628 · Cited by 160
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
Tentori, L., Lacal, P. M., Muzi, A., Dorio, A. S., Leonetti, C., Scarsella, M., Ruffini, F., Xu, W., Min, W., Stoppacciaro, A., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.010 · Cited by 159
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Wang, Z. C., Birkbak, N. J., Culhane, A. C., Drapkin, R., Fatima, A., Tian, R., Schwede, M., Alsop, K., Daniels, K. E., Piao, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0857 · Cited by 159
Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R. A., Silver, D. P., Sledge, G. W., & Carey, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0939 · Cited by 159
DEAD Box 1 Facilitates Removal of RNA and Homologous Recombination at DNA Double-Strand Breaks
Li, L., Germain, D. R., Poon, H.-Y., Hildebrandt, M. R., Monckton, E. A., McDonald, D., Hendzel, M. J., & Godbout, R. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00415-16 · Cited by 159
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
Lowery, M. A., Kelsen, D. P., Capanu, M., Smith, S., Lee, J. W., Stadler, Z. K., Moore, M. J., Kindler, H. L., Golan, T., Segal, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.004 · Cited by 159
Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells
Alimbetov, D. S., Askarova, S., Umbayev, B. A., Davis, T., & Kipling, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061690 · Cited by 159
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 160
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.191 · Cited by 158
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Kaplan, A. R., Gueble, S. E., Liu, Y., Oeck, S., Kim, H., Yun, Z., & Glazer, P. M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4508 · Cited by 158
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
Park, J. H., Ahn, J. H., & Kim, S. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000357 · Cited by 158
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Keung, M., Wu, Y., & Vadgama, J. V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040435 · Cited by 158
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Carreira, S., Porta, N., Arce‐Gallego, S., Seed, G., Llop‐Guevara, A., Bianchini, D., Rescigno, P., Paschalis, A., Bertan, C. M., Baker, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0007 · Cited by 158
A new wave of innovations within the DNA damage response
Li, Q., Qian, W., Zhang, Y., Hu, L., Chen, S., & Xia, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01548-8 · Cited by 166
PARPs and the DNA damage response
Sousa, F. G., Matuo, R., Soares, D. G., Escargueil, A. E., Henriques, J. A. P., Larsen, A. K., & Saffi, J. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs132 · Cited by 157
The systemic treatment of recurrent ovarian cancer revisited
Baert, T., Ferrero, A., Sehouli, J., O’Donnell, D. M., González-Martı́n, A., Joly, F., van der Velden, J., Blecharz, P., Tan, D. S. P., Querleu, D., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.015 · Cited by 157
Genomic instability in breast cancer: Pathogenesis and clinical implications
Kwei, K. A., Kung, Y., Salari, K., Holcomb, I. N., & Pollack, J. R. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.001 · Cited by 157
Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase
Alli, E., Sharma, V. B., Sunderesakumar, P., & Ford, J. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4016 · Cited by 156
TP53 mutations in epithelial ovarian cancer
Zhang, Y., Cao, L., Nguyen, D., & Lu, H. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.40 · Cited by 156
Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: Mechanistic insights
Thompson, L. H., & Hinz, J. M. (2009) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2009.02.003 · Cited by 155
Ubiquitylation, neddylation and the DNA damage response
Brown, J. S., & Jackson, S. P. (2015) · Open Biology · doi:10.1098/rsob.150018 · Cited by 155
Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing
Iacobuzio–Donahue, C. A., Velculescu, V. E., Wolfgang, C. L., & Hruban, R. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0315 · Cited by 155
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
Hassan, R., Morrow, B., Thomas, A., Walsh, T., Lee, M. K., Gülsüner, S., Gadiraju, M., Panou, V., Gao, S., Mian, I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821510116 · Cited by 155
The role of DNA repair pathways in cisplatin resistant lung cancer
O’Grady, S., Finn, S. P., Cuffe, S. D., Richard, D. J., O'Byrne, K. J., & Barr, M. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.003 · Cited by 154
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
Johannes, J. W., Balazs, A., Barratt, D. G., Biśta, M., Chuba, M. D., Cosulich, S. C., Critchlow, S. E., Degorce, S. L., Fruscia, P. D., Edmondson, S. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01012 · Cited by 154
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Fizazi, K. S., Azad, A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., Jones, R. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02704-x · Cited by 154
Familial pancreatic cancer—current knowledge
Bartsch, D. K., Gress, T. M., & Langer, P. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.111 · Cited by 153
Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities
de Vries, G., Rosas-Plaza, X., van Vugt, M. A. T. M., Gietema, J. A., & de Jong, S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102054 · Cited by 153
Molecular Signatures of Pancreatic Cancer
Hong, S., Park, J. Y., Hruban, R. H., & Goggins, M. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0566-ra.1 · Cited by 152
RAD-ical New Insights into RAD51 Regulation
Sullivan, M. R., & Bernstein, K. A. (2018) · Genes · doi:10.3390/genes9120629 · Cited by 152
Reality CHEK: Understanding the biology and clinical potential of CHK1
Neizer‐Ashun, F., & Bhattacharya, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.016 · Cited by 152
Advances in using PARP inhibitors to treat cancer
Kummar, S., Chen, A. P., Parchment, R. E., Kinders, R. J., Ji, J., Tomaszewski, J. E., & Doroshow, J. H. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-25 · Cited by 151
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
Pillay, N., Tighe, A., Nelson, L., Littler, S., Coulson‐Gilmer, C., Bah, N. K., Golder, A., Bakker, B., Spierings, D. C. J., James, D. I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.004 · Cited by 151
Recent advancement of piperidine moiety in treatment of cancer- A review
Goel, P., Alam, O., Naim, M. J., Nawaz, F., Iqbal, M., & Alam, I. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.017 · Cited by 150
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
Hewitt, G., Borel, V., Segura‐Bayona, S., Takaki, T., Ruis, P., Bellelli, R., Lehmann, L. C., Sommerová, L., Vančevska, A., Tomás‐Loba, A., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.12.006 · Cited by 150
Aurora kinase A, a synthetic lethal target for precision cancer medicine
Mou, P. K., Yang, E. J., Shi, C., Ren, G., Tao, S., & Shim, J. S. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00635-6 · Cited by 150
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
Nonnekens, J., van Kranenburg, M., Beerens, C. E. M. T., Suker, M., Doukas, M., van Eijck, C. H. J., de Jong, M., & van Gent, D. C. (2016) · Theranostics · doi:10.7150/thno.15311 · Cited by 149
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0247 · Cited by 149
Familial Pancreatic Cancer
Brune, K. A., & Klein, A. P. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_5 · Cited by 149
PARP inhibitors: the race is on
Brown, J. S., Kaye, S. B., & Yap, T. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.67 · Cited by 149
Chromatin and the DNA damage response: The cancer connection
Luijsterburg, M. S., & van Attikum, H. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.06.001 · Cited by 148
Protein post-translational modifications in the regulation of cancer hallmarks
Wang, H., Yang, L., Liu, M., & Luo, J. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00464-3 · Cited by 148
PARP inhibitors in ovarian cancer: Current status and future promise
Liu, J. F., Konstantinopoulos, P. A., & Matulonis, U. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.039 · Cited by 147
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
Zheng, F., Zhang, Y., Chen, S., Weng, X., Rao, Y., & Hongmei, F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109661 · Cited by 147
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
Papeo, G., Posteri, H., Borghi, D., Busel, A. A., Caprera, F., Casale, E., Ciomei, M., Cirla, A., Corti, E., D’Anello, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00680 · Cited by 147
Targeted cancer therapies based on the inhibition of DNA strand break repair
O’Connor, M. J., Martin, N. M. B., & Smith, G. C. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210879 · Cited by 147
PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasisPreprint
Kim, D.-S., Challa, S., Jones, A., & Kraus, W. L. (2020) · Genes & Development · doi:10.1101/gad.334433.119 · Cited by 149
Perspectives in the treatment of pancreatic adenocarcinoma
Arregui, A. C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i31.9297 · Cited by 146
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
Miller, T. W., & Hosford, S. R. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52762 · Cited by 146
AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013
Harbeck, N., Scharl, A. J., Thomssen, C., & Müller, V. (2013) · Breast Care · doi:10.1159/000353590 · Cited by 146
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Min, A., Im, S., Yoon, Y., Song, S., Nam, H.-J., Hur, H.-S., Kim, H., Lee, K.-H., Han, S., Oh, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0950 · Cited by 146
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Kaina, B., & Christmann, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.007 · Cited by 147
Parthanatos and its associated components: Promising therapeutic targets for cancer
Zhou, Y., Liu, L., Tao, S., Yao, Y., Wang, Y., Wei, Q., Shao, A., & Deng, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105299 · Cited by 146
Rapid Detection and Signaling of DNA Damage by PARP-1
Pandey, N., & Black, B. E. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.01.014 · Cited by 146
Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis
Martín‐Oliva, D., Aguilar‐Quesada, R., O’Valle, F., Muñoz‐Gámez, J. A., Martínez‐Romero, R., del Moral, R. G., de Almodóvar, J. M. R., Villuendas, R., Piris, M. A., & Oliver, F. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3050 · Cited by 146
Noncanonical views of homology-directed DNA repairPreprint
Verma, P., & Greenberg, R. A. (2016) · Genes & Development · doi:10.1101/gad.280545.116 · Cited by 146
Mammalian Rif1 contributes to replication stress survival and homology-directed repair
Buonomo, S. B. C., Wu, Y., Ferguson, D. O., & de Lange, T. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200902039 · Cited by 145
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
Brighty, G. J., Botham, R. C., Li, S., Nelson, L. T., Mortenson, D. E., Li, G., Morisseau, C. H. P., Wang, H., Hammock, B. D., Sharpless, K. B., et al. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0530-4 · Cited by 148
Context-Dependent Glioblastoma–Macrophage/Microglia Symbiosis and Associated Mechanisms
Xuan, W., Lesniak, M. S., James, C. D., Heimberger, A. B., & Chen, P. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.004 · Cited by 147
ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
Mohni, K. N., Kavanaugh, G. M., & Cortez, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3229 · Cited by 143
ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis
Lu, Y., Ju, H., Liu, Z., Chen, D.-L., Wang, Y., Zhao, Q., Wu, Q.-N., Zeng, Z.-L., Qiu, H.-B., Hu, P.-S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3155 · Cited by 143
DNA end resection by CtIP and exonuclease 1 prevents genomic instability
Eid, W., Steger, M., El‐Shemerly, M., Ferretti, L. P., Peña-Dı́az, J., König, C., Valtorta, E., Sartori, A. A., & Ferrari, S. M. (2010) · EMBO Reports · doi:10.1038/embor.2010.157 · Cited by 142
ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
Palma, J. P., Wang, Y., Rodriguez, L. E., Montgomery, D., Ellis, P. A., Bukofzer, G. T., Niquette, A. L., Liu, X., Shi, Y., Lasko, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1245 · Cited by 142
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Drost, R., Dhillon, K. K., van der Gulden, H. M. L., van der Heijden, I., Brandsma, I., Cruz, C., Chondronasiou, D., Castroviejo‐Bermejo, M., Boon, U., Schut, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci70196 · Cited by 142
BRCA mutation in ovarian cancer: testing, implications and treatment considerations
Neff, R. T., Senter, L. A., & Salani, R. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017714993 · Cited by 142
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
Jain, P. G., & Patel, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.024 · Cited by 142
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Boussios, S., Abson, C., Moschetta, M., Rassy, E., Karathanasi, A., Bhat, T., Ghumman, F. I. A., Sheriff, M., & Pavlidis, N. A. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00301-8 · Cited by 142
ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
Verma, P., Zhou, Y., Cao, Z., Deraska, P. V., Deb, M., Arai, E., Li, W., Shao, Y., Puentes, L. N., Li, Y. H., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-020-00624-3 · Cited by 142
Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate
Witney, T. H., Kettunen, M. I., Hu, D. ‐., Gallagher, F. A., Bohndiek, S. E., Napolitano, R., & Brindle, K. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605945 · Cited by 141
Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes
Al‐Ejeh, F., Kumar, R., Wiegmans, A. P., Lakhani, S. R., Brown, M. P., & Khanna, K. K. (2010) · Oncogene · doi:10.1038/onc.2010.407 · Cited by 141
Identifying people at a high risk of developing pancreatic cancer
Klein, A. P. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3420 · Cited by 141
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
Haynes, B. M., Murai, J., & Lee, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.003 · Cited by 141
Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis
Bukhari, A. B., Lewis, C. W., Pearce, J. J., Luong, D., Chan, G. K. T., & Gamper, A. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122622 · Cited by 141
Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA -deficient cells to PARP inhibitors
Fugger, K., Bajrami, I., dos Santos, M. S., Young, S. J., Kunzelmann, S., Kelly, G. P., Hewitt, G., Patel, H., Goldstone, R. J., Carell, T., et al. (2021) · Science · doi:10.1126/science.abb4542 · Cited by 141
A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants
Bouwman, P., van der Gulden, H., van der Heijden, I., Drost, R., Klijn, C. N., Prasetyanti, P., Pieterse, M., Wientjens, E., Seibler, J., Hogervorst, F. B. L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0094 · Cited by 140
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Ang, J. E., Gourley, C., Powell, C. B., High, H. A., Shapira‐Frommer, R., Castonguay, V., Grève, J. D., Atkinson, T., Yap, T. A., Sandhu, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1262 · Cited by 140
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
Ding, X., Chaudhuri, A. R., Callén, E., Pang, Y., Biswas, K., Klarmann, K. D., Martin, B. K., Burkett, S. S., Cleveland, L., Stauffer, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12425 · Cited by 140
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 144
JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1–mediated chromatin response to DNA breaks
Watanabe, S., Watanabe, K., Akimov, V., Bártková, J., Blagoev, B., Lukas, J., & Bártek, J. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2702 · Cited by 139
PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant Transformation
Rodríguez, M. I., Peralta-Leal, A., O’Valle, F., Rodríguez-Vargas, J. M., González-Flores, A., Majuelos‐Melguizo, J., López, L., Serrano, S., de Herreros, A. G., Rodríguez-Manzaneque, J. C., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003531 · Cited by 140
Mutational Signatures in Breast Cancer: The Problem at the DNA Level
Nik‐Zainal, S., & Morganella, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2810 · Cited by 139
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 140
PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
Fraser, M. E., Zhao, H. W., Luoto, K. R., Lundin, C., Coackley, C. L., Chan, N. H. L., Joshua, A. M., Bismar, T. A., Evans, A. J., Helleday, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2189 · Cited by 138
Self-citation

Authors: Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T.
Affiliations: University of Sheffield (GB)
Stockholm University (SE)
Newcastle University (GB)
Corresponding author: Helleday, Thomas
ORCID: Bryant, Helen E.
Thomas, Huw D.
Curtin, Nicola J.
Helleday, Thomas
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2005-04-14
Volume: 434
Issue: 7035
Pages: 913-917
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature03443
OpenAlex: W2009007206
Cited by: 5,198
References: 26
Citations by year: 2026: 213 · 2025: 256 · 2024: 286 · 2023: 355 · 2022: 355 · 2021: 396 · 2020: 388 · 2019: 282 · 2018: 290 · 2017: 273 · 2016: 265 · 2015: 230 · 2014: 243 · 2013: 223 · 2012: 213
FWCI: 56.59
Type: journal article
Language: en
Update notices: erratum (2007-05-17)
Open access: green
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Cancer Institute (F31CA260794)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: PARP inhibitors, BRCA2 deficiency, homologous recombination, synthetic lethality, breast cancer, PARP1, DNA repair, replication fork collapse, single-strand breaks, γH2AX foci, RAD51 foci, base excision repair
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Benzodiazepines, DNA Damage, DNA Repair, DNA Replication, Mice, Nude, Neoplasms, Poly(ADP-ribose) Polymerases, Xenograft Model Antitumor Assays, Genes, BRCA2, BRCA2 Protein, Cell Line, Tumor, Mice, Azulenes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks